Page last updated: 2024-11-06

droxidopa

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Droxidopa is a prodrug of norepinephrine, a neurotransmitter that plays a vital role in the sympathetic nervous system. It is synthesized from L-dopa, a precursor to dopamine, by introducing a hydroxyl group at the beta position. Droxidopa is primarily used to treat neurogenic orthostatic hypotension (NOH), a condition characterized by low blood pressure upon standing. It acts by increasing norepinephrine levels in the body, leading to vasoconstriction and an increase in blood pressure. Droxidopa is studied extensively because of its potential to improve quality of life for patients with NOH by reducing symptoms such as dizziness, lightheadedness, and fainting. Research is ongoing to explore its efficacy and safety in other conditions, including chronic fatigue syndrome, narcolepsy, and attention-deficit/hyperactivity disorder.'

Droxidopa: A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

droxidopa : A serine derivative that is L-serine substituted at the beta-position by a 3,4-dihydroxyphenyl group. A prodrug for noradrenalone, it is used for treatment of neurogenic orthostatic hypotension [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6999030
CHEMBL ID2355249
SCHEMBL ID129756
MeSH IDM0023229
PubMed CID92974
CHEMBL ID2103827
CHEBI ID31524
SCHEMBL ID134299
MeSH IDM0023229

Synonyms (121)

Synonym
dtxcid4026422
cas-23651-95-8
tox21_112167
SCHEMBL129756
tox21_112167_1
NCGC00344531-01
CHEMBL2355249
dl threo 3,4 dihydroxyphenylserine
3,4 threo dops
threo dops
l-tyrosine, beta,3-dihydroxy-, (beta-r)-
einecs 223-480-5
threo-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropionic acid
3,4-threo-dops
l-tyrosine, beta,3-dihydroxy-, threo-
serine, 3-(3,4-dihydroxyphenyl)-, l-threo-
brn 2852792
l-threo-3-(3,4-dihydroxyphenyl)serine
dl-threo-dihydroxyphenylserine
serine, 3-(3,4-dihydroxyphenyl)-, dl-threo-
dl-threo-dops
(-)-(2s,3r)-2-amino-3-hydroxy-3-(3,4-dihydroxyphenyl)propionic acid
beta,3-dihydroxy-dl-tyrosine threo-
dl-tyrosine, beta,3-dihydroxy-, threo-
l-threodops
3,4-dihydroxyphenylserine
threo-dops
dl-threo-3-(3,4-dihydroxyphenyl)serine
droxidopa [latin]
(-)-threo-3-(3,4-dihydroxyphenyl)-l-serine
threo-dopaserine
dl-threo-3,4-dihydroxyphenylserine
threo-beta,3-dihydroxy-dl-tyrosine
3916-18-5
droxidopa
northera
dops
l-dops
23651-95-8
dops (tn)
droxidopa (jp17/usan/inn)
D01277
northera (tn)
l-dihydroxyphenylserine
l-threo-dihydroxyphenylserine
DB06262
(2s,3r)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid
dtxsid6046422 ,
A816824
(2s,3r)-3-(3,4-dihydroxyphenyl)-2-amino-3-hydroxypropanoic acid
1-14-00-00685 (beilstein handbook reference)
unii-24a0v01wks
24a0v01wks ,
threo-dihydroxyphenylserine
l-threo-dops
chebi:31524 ,
CHEMBL2103827
j7a92w69l7 ,
droxidopa [usan:inn:jan]
sm 5688
norethra
unii-j7a92w69l7
droxydopa
l-threo 3,4-dihydroxyphenylserine
AKOS015889899
S3041
sm-5688
gtpl7391
CCG-222060
HY-13458
SCHEMBL134299
(-)-(2s,3r)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid
droxidopa [mart.]
droxidopa [mi]
l-tyrosine, .beta.,3-dihydroxy-, (.beta.r)-
droxidopa [vandf]
droxidopa [usan]
droxidopa [jan]
threo-3,4-dihydroxyphenylserine, l-
droxidopa [who-dd]
droxidopa [orange book]
droxidopa [inn]
(-)-(2s,3r)-2-amino-3-hydroxy-3-(3,4-dihydroxyphenyl)propanoic acid
droxidopum
(betar)-beta,3-dihydroxy-l-tyrosine
(2s,3r)-3,4-dihydroxy-phenylserine
dl-threo-droxidopa
3,4-dihydroxyphenylserine-threo, dl-
d-tyrosine, .beta.,3-dihydroxy-, (.beta.s)-rel-
dl-tyrosine, .beta.,3-dihydroxy-, threo-
Q-201050
D4235
(2s,3r)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropionic acid
AB01566868_01
dl-threo-beta-(3,4-dihydroxyphenyl)serine
bdbm50103611
sm5688
sr-01000883755
SR-01000883755-1
l-dops, >=98% (hplc)
AS-61328
1260173-94-1
droxidopa (l-dops,sm-5688)
h-dl--(3,4-dihydroxyphenyl)-dl-ser-oh
l-threo dops
QXWYKJLNLSIPIN-JGVFFNPUSA-N
BCP06516
(2rs,3rs)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxy-propanoic acid
droxidopa (l-dops)
23651-95-8,1260173-94-1(hcl)
mfcd00799030
Q907853
DTXSID201017236
NCGC00344531-04
l-tyrosine, beta,3-dihydroxy-, (betar)-
D90266
dl-threo- beta -(3,4-dihydroxyphenyl)serine
EN300-9430063
c01ca27
droxidopa (mart.)
droxidopa (latin)

Research Excerpts

Overview

Droxidopa is a norepinephrine precursor that improves symptoms of neurogenic orthostatic hypotension in conditions such as Parkinson disease, multiple system atrophy, and pure autonomic failure by inducing a pressor effect. The drug is a synthetic amino acid that is converted to nore Pinephrine by dopa-decarboxylase, the same enzyme that converts levodopa into dopamine.

ExcerptReferenceRelevance
"Droxidopa is a norepinephrine precursor that improves symptoms of neurogenic orthostatic hypotension in conditions such as Parkinson disease, multiple system atrophy, and pure autonomic failure by inducing a pressor effect. "( Cognitive and Behavioral Changes in Patients Treated With Droxidopa for Neurogenic Orthostatic Hypotension: A Retrospective Review.
Biaggioni, I; Claassen, DO; Hartman, A; McDonell, KE; Robertson, D; Shibao, CA, 2019
)
2.2
"Droxidopa is an oral treatment for the stepwise treatment of neurogenic orthostatic hypotension from autonomic dysfunction. "( Droxidopa as an effective treatment for refractory neurogenic orthostatic hypotension and reflex bradycardia in amyloid light-chain amyloidosis: a case report.
Ho, AH; Kinter, CW; Krakow, D; Neelam, AR; Wight, J, 2020
)
3.44
"Droxidopa is a norepinephrine precursor approved for the treatment of neurogenic OH (nOH) associated with autonomic failure that is commonly used in the outpatient setting, but there are currently no data regarding the safety and efficacy of droxidopa initiation in medically complex patients."( Initiation of droxidopa during hospital admission for management of refractory neurogenic orthostatic hypotension in severely ill patients.
Biaggioni, I; Diedrich, A; McDonell, KE; Muldowney, JAS; Peltier, AC; Preheim, BA; Robertson, D; Shibao, CA, 2019
)
1.6
"Droxidopa is a synthetic amino acid that is converted to norepinephrine by dopa-decarboxylase, the same enzyme that converts levodopa into dopamine in the treatment of Parkinson disease."( New developments in the management of neurogenic orthostatic hypotension.
Biaggioni, I, 2014
)
1.12
"Droxidopa is an oral prodrug of norepinephrine."( Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B).
Hauser, RA; Hewitt, LA; Isaacson, S; Lisk, JP; Rowse, G, 2015
)
2.58
"Droxidopa is a safe and effective drug for the short-term management of NOH symptoms. "( Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension.
Abdelazeim, B; Elgebaly, A; Gadelkarim, M; Mattar, O; Negida, A; Salah, R, 2016
)
2.14
"Droxidopa is a prodrug of norepinephrine indicated for the treatment of orthostatic dizziness, lightheadedness, or the "feeling that you are about to black out" in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure including Parkinson disease (PD). "( Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension.
Hauser, RA; Heritier, S; Hewitt, LA; Isaacson, SH; Rowse, GJ,
)
3.02
"Droxidopa is an orally active prodrug that significantly improved dizziness/lightheadedness measured using the Orthostatic Hypotension Symptom Assessment (OHSA) Item 1 in patients with neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson disease, multiple system atrophy, and pure autonomic failure), dopamine β-hydroxylase deficiency, or nondiabetic autonomic neuropathy. "( Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension.
François, C; Hauser, RA; Hewitt, LA; Rowse, GJ; Vo, P, 2016
)
2.15
"Droxidopa is an orally administered amino acid that is converted to norepinephrine and thought to improve both blood pressure and symptoms in patients with orthostatic intolerance."( Droxidopa in the Treatment of Postural Orthostatic Tachycardia Syndrome.
Dasa, O; Grubb, B; Karabin, B; Pacenta, A; Ruzieh, M,
)
2.3

Effects

ExcerptReferenceRelevance
"Droxidopa has been approved for the treatment of neurogenic orthostatic hypotension (NOH) under the US Food and Drug Administration accelerated approval program, which warrants confirmatory evidence on long-term efficacy of droxidopa. "( Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension.
Abdelazeim, B; Elgebaly, A; Gadelkarim, M; Mattar, O; Negida, A; Salah, R, 2016
)
2.14

Treatment

Droxidopa is an oral treatment for the stepwise treatment of neurogenic orthostatic hypotension from autonomic dysfunction. Treatment with droxidopa appears to reduce falls in PD patients.

ExcerptReferenceRelevance
"Droxidopa is an oral treatment for the stepwise treatment of neurogenic orthostatic hypotension from autonomic dysfunction. "( Droxidopa as an effective treatment for refractory neurogenic orthostatic hypotension and reflex bradycardia in amyloid light-chain amyloidosis: a case report.
Ho, AH; Kinter, CW; Krakow, D; Neelam, AR; Wight, J, 2020
)
3.44
"Droxidopa-treated rats also showed a decreased ratio of p-eNOS/eNOS and p-AKT/AKT and increased activity of RhoK in SMA."( Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats.
Augustin, S; Brull, A; Coll, M; Esteban, R; Ezkurdia, N; Genescà, J; Guardia, J; Martell, M; Raurell, I; Rodriguez, S, 2012
)
2.54
"Treatment with droxidopa appears to reduce falls in PD patients with symptomatic neurogenic orthostatic hypotension, but this finding must be confirmed."( Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension.
Hauser, RA; Heritier, S; Hewitt, LA; Isaacson, SH; Rowse, GJ,
)
1.93
"Treatment with droxidopa increases BP levels and improves symptoms related to refractory OH using all physical and pharmacological measures available. "( Refractory orthostatic hypotension in a patient with a spinal cord injury: Treatment with droxidopa.
Canosa-Hermida, E; Ferreiro-Velasco, ME; Mondelo-García, C; Montoto-Marqués, A; Rodríguez-Sotillo, A; Salvador-de la Barrera, S; Vizoso-Hermida, JR, 2018
)
1.06

Toxicity

Droxidopa is a safe and effective drug for the short-term management of NOH symptoms. None of the adverse events were significantly higher in the case of droxidopa compared to placebo.

ExcerptReferenceRelevance
" Also assessed were changes from baseline in systolic BP (SBP) and diastolic BP (DBP) during and after HD; number of hypotension-induced interventions and symptoms; and adverse events."( A randomized, placebo-controlled, phase 2 study of the efficacy and safety of droxidopa in patients with intradialytic hypotension.
Hariachar, S; Hewitt, LA; Vannorsdall, MD, 2015
)
0.65
" None of the adverse events were significantly higher in the case of droxidopa compared to placebo."( Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension.
Abdelazeim, B; Elgebaly, A; Gadelkarim, M; Mattar, O; Negida, A; Salah, R, 2016
)
0.93
"Droxidopa is a safe and effective drug for the short-term management of NOH symptoms."( Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension.
Abdelazeim, B; Elgebaly, A; Gadelkarim, M; Mattar, O; Negida, A; Salah, R, 2016
)
2.14
" Rates of serious adverse events (AEs), cardiac-related AEs, and supine hypertension were 24%, 5%, and 5%, respectively."( Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension.
Isaacson, S; Kalu, U; Rowse, GJ; Vernino, S; White, WB; Ziemann, A, 2016
)
0.76
" Safety was assessed through adverse event (AE) reports and vital signs."( Safety and Durability of Effect with Long-Term, Open-Label Droxidopa Treatment in Patients with Symptomatic Neurogenic Orthostatic Hypotension (NOH303).
Isaacson, S; Rowse, GJ; Shill, HA; Vernino, S; Ziemann, A, 2016
)
0.68

Pharmacokinetics

ExcerptReferenceRelevance
" The method was successfully applied to a pharmacokinetic study of droxidopa in healthy Chinese volunteers."( Development and validation of a UPLC-MS/MS method for quantitation of droxidopa in human plasma: Application to a pharmacokinetic study.
Pei, J; Song, X; Sun, Z; Wang, H; Yang, G; Zhang, Q; Zhou, J, 2016
)
0.9

Compound-Compound Interactions

ExcerptReferenceRelevance
" When a levodopa or droxidopa preparation, judged as grade 3 in screening, was concomitantly administered with an iron preparation, a significant reduction in bioavailability of the test drug was observed, indicating possible drug interaction between the test drug and oral iron."( [Simple method for precognition of drug interaction between oral iron and phenolic hydroxyl group-containing drugs].
Kamimura, N; Murayama, N; Sunagane, N; Terawaki, Y; Uruno, T; Yoshinobu, E, 2005
)
0.65

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" When a levodopa or droxidopa preparation, judged as grade 3 in screening, was concomitantly administered with an iron preparation, a significant reduction in bioavailability of the test drug was observed, indicating possible drug interaction between the test drug and oral iron."( [Simple method for precognition of drug interaction between oral iron and phenolic hydroxyl group-containing drugs].
Kamimura, N; Murayama, N; Sunagane, N; Terawaki, Y; Uruno, T; Yoshinobu, E, 2005
)
0.65

Dosage Studied

ExcerptRelevanceReference
" The degree of increase in the norepinephrine (NE) concentrations was closely correlated to the dosage of L-threo-DOPS."( Effect of a synthetic norepinephrine precursor, L-threo-3,4- dihydroxyphenylserine on the total norepinephrine concentration in the cerebrospinal fluid of parkinsonian patients.
Abe, T; Nozaki, Y; Takahashi, J; Takahashi, S; Tohgi, H; Ueno, M, 1990
)
0.28
" A non-anorectic dosage of L110-140 (3."( The role of norepinephrine in feeding behavior.
Davies, RF; Panksepp, J; Rossi, J; Zolovick, AJ, 1982
)
0.26
" The hypothesis of ephaptic transmission was supported by meaningful decrease of muscle sympathetic activity detected by microneurography before and after the dosage of L-DOPS, which effectively suppressed the pain as well as other alpha-stimulant, midodrine hydrochloride."( [Pain caused by ephaptic transmission occurring in the recovery phase of diabetic vascular mononeuropathy was effectively suppressed with L-threo-3,4-dihydroxyphenyl-serine].
Inoue, K; Kunimoto, M; Ohshima, F, 1998
)
0.3
" Final dosage was maintained for six weeks."( L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure.
Aragishi, A; Braune, S; Keeling, JE; Mathias, CJ; Senard, JM; Taylor, MD; Watson, L, 2001
)
0.57
" Blood samples for pharmacokinetic analysis were collected before dosing and after ECG data collection."( Impact of the Norepinephrine Prodrug Droxidopa on the QTc Interval in Healthy Individuals.
Hewitt, LA; Mehdirad, AA; White, WB, 2018
)
0.75
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
prodrugA compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
vasoconstrictor agentDrug used to cause constriction of the blood vessels.
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
L-tyrosine derivativeA proteinogenic amino acid derivative resulting from reaction of L-tyrosine at the amino group or the carboxy group, or from the replacement of any hydrogen of L-tyrosine by a heteroatom.
catecholsAny compound containing an o-diphenol component.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency5.30910.000811.382244.6684AID686979
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency11.88320.003041.611522,387.1992AID1159552
Histone H2A.xCricetulus griseus (Chinese hamster)Potency39.07620.039147.5451146.8240AID1224845
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency29.01450.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency17.33870.000627.21521,122.0200AID743202; AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nuclear receptor subfamily 1 group I member 2Homo sapiens (human)EC50 (µMol)1.60200.00203.519610.0000AID1215087; AID1215094
Nuclear receptor subfamily 1 group I member 2Rattus norvegicus (Norway rat)EC50 (µMol)63.10000.01004.139410.0000AID1215090
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
negative regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
signal transductionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
steroid metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of gene expressionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic catabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic transportNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
cell differentiationNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor activityNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
protein bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
zinc ion bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
nucleoplasmNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
transcription regulator complexNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear bodyNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intermediate filament cytoskeletonNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
chromatinNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nucleusNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (43)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1215090Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1215094Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1215091Activation of human PXR expressed in human HepG2 (DPX-2) cells up to 46 uM after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1215089Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis relative to rifampicin2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1215097Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis relative to dexamethasone2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1215095Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay relative to SR128132011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID681113TP_TRANSPORTER: inhibition of L-tryptophan uptake in Xenopus laevis oocytes2001The Journal of biological chemistry, May-18, Volume: 276, Issue:20
Expression cloning of a Na+-independent aromatic amino acid transporter with structural similarity to H+/monocarboxylate transporters.
AID1215087Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (364)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990125 (34.34)18.7374
1990's91 (25.00)18.2507
2000's32 (8.79)29.6817
2010's88 (24.18)24.3611
2020's28 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 66.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index66.53 (24.57)
Research Supply Index5.99 (2.92)
Research Growth Index4.75 (4.65)
Search Engine Demand Index114.10 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (66.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials36 (9.92%)5.53%
Reviews0 (0.00%)6.00%
Reviews49 (13.50%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies64 (17.63%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
Other214 (58.95%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (39)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase II, Double-Blind, Placebo-Controlled Randomized Crossover Study to Assess the Clinical Benefit and Safety of Droxidopa in the Treatment of Freezing of Gait Symptoms in Patients With Parkinson's Disease [NCT01331122]Phase 1/Phase 20 participants (Actual)Interventional2012-04-30Withdrawn(stopped due to Never initiated. Withdrawn by sponsor.)
RESTORE: A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy [NCT02586623]Phase 4453 participants (Actual)Interventional2016-02-11Completed
A Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's Disease [NCT03034564]Phase 41 participants (Actual)Interventional2017-01-31Terminated(stopped due to Site staffing)
Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH) [NCT03567447]Phase 210 participants (Anticipated)Interventional2018-08-17Recruiting
Phase I/II Study of NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Adults With Occipital Horn Syndrome: Double-blind Placebo-controlled Randomized Crossover Clinical Trial [NCT04977388]Phase 1/Phase 26 participants (Anticipated)Interventional2021-07-12Recruiting
A Phase II, Double-Blind, Placebo-Controlled, Crossover Study to Assess Clinical Benefit and Safety of Droxidopa in the Treatment of Parkinson's Disease [NCT02066571]Phase 220 participants (Anticipated)Interventional2015-03-31Enrolling by invitation
A Randomized, Open-Label, Three-Period, Three-Sequence, Single-Dose Crossover and Separate Three-Daily-Dose Treatment Period Study Comparing the Pharmacokinetic Profiles Following Oral Dosing of 300 mg of Droxidopa in the Fed Versus Fasted State, the Bioe [NCT01149629]Phase 124 participants (Anticipated)Interventional2010-07-31Completed
A Dose Response Trial of Droxidopa to Treat Hypotension in Persons With SCI [NCT01354158]Phase 111 participants (Actual)Interventional2011-05-31Completed
Technology-Based Objective Measures for Gait and Postural Assessment in Parkinson Disease Patients With Orthostatic Hypotension: Feasibility and Effect-Size Finding Study [NCT04510922]Phase 49 participants (Actual)Interventional2019-02-11Completed
Evaluate the Long-term (3 Months) Efficacy of L-threo DOPS (DroxiDopa) on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With Multiple System Atrophy (MSA). Comparative Study Versus Placebo [NCT02071459]Phase 2/Phase 3107 participants (Actual)Interventional2014-01-21Completed
Effects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's Disease [NCT03173781]21 participants (Actual)Interventional2016-04-30Completed
Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury [NCT03602014]Phase 422 participants (Actual)Interventional2018-06-01Completed
Long Term Treatment With L-DOPS [NCT00889135]0 participants Expanded Access2004-09-30Approved for marketing
Phase III, Multi-Center, Study to Assess the Clinical Effect of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic NOH [NCT00633880]Phase 3181 participants (Actual)Interventional2008-01-31Completed
Phase III, Multi-Center, Study to Assess the Clinical Effect of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic NOH [NCT00782340]Phase 3263 participants (Actual)Interventional2008-09-30Completed
A Phase II, Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Assess the Clinical Benefit and Safety of Droxidopa in Patients With Intradialytic Hypotension [NCT00657046]Phase 285 participants (Actual)Interventional2007-12-31Completed
An Open-label Study, to Assess the Long-term Safety and Clinical Benefit of Droxidopa in Subjects With PAF, Dopamine Beta Hydroxylase Deficiency or Non-diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension [NCT00738062]Phase 3103 participants (Actual)Interventional2008-01-31Completed
A Multi-center, Double-blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of Droxidopa in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients With Parkinson's Disease [NCT01176240]Phase 3225 participants (Actual)Interventional2010-06-30Completed
A Multi-center, Open-label Study to Assess the Long-term Safety of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension [NCT01132326]Phase 3350 participants (Actual)Interventional2009-01-31Completed
Northera Improves Postural Tachycardia Syndrome (POTS) and Postural [NCT02558972]Phase 230 participants (Anticipated)Interventional2015-09-30Active, not recruiting
L-Dihydroxyphenylserine (L-DOPS) for Norepinephrine Deficiency: Interactions With Carbidopa and Entacapone [NCT00547911]Phase 1/Phase 214 participants (Actual)Interventional2007-10-31Terminated(stopped due to Study terminated due to contamination droxidopa)
A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Response, Study To Assess The Clinical Benefit Of Droxidopa and Droxidopa/Carbidopa In Subjects With Fibromyalgia [NCT01323374]Phase 2120 participants (Actual)Interventional2009-01-31Completed
A Double-Blind Randomized Crossover Trial to Define the Ecg Effects of Droxidopa Using a Clinical and a Supratherapeutic Dose Compared With Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: a Thorough ECG Trial [NCT01327066]Phase 152 participants (Actual)Interventional2011-03-31Completed
A Phase II, Randomized, Double Blind, Cross-over, Placebo-controlled Study on Norepinephrine Replenishment Therapy Using L-DOPS in Congenital Insensitivity to Pain With Anhidrosis Patients [NCT02624310]Phase 20 participants (Actual)Interventional2016-01-31Withdrawn
Effect of L-Dihydoxyphenylserine (L-DOPS, Northera) a Central and Peripheral Norepinephrine Agent on Locomotion, Postural Stability (Balance), and Fall Risk Reduction in Parkinson Disease (PD) [NCT02812147]Phase 220 participants (Anticipated)Interventional2016-05-31Active, not recruiting
Treatment of Orthostatic Hypotension in Individuals With Spinal Cord Injury [NCT05839652]Phase 425 participants (Anticipated)Interventional2023-07-01Not yet recruiting
Norepinephrine-targeted Therapy for Action Control in Parkinson Disease [NCT03115827]Phase 415 participants (Actual)Interventional2017-04-18Completed
A Phase I, Multi-Center, Open-Label Study to Examine the Pharmacokinetics of a Single Dose of Droxidopa in Subjects With Renal Impairment Compared to Healthy Volunteers [NCT01468259]Phase 10 participants (Actual)Interventional2012-10-31Withdrawn
An Open-Label Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome [NCT00977171]Phase 23 participants (Actual)Interventional2010-07-31Terminated(stopped due to Enrollment issues.)
Treatment of Hypotensive Patients Having a Unique Pattern of Autonomic Symptoms [NCT00581477]Phase 2/Phase 38 participants (Actual)Interventional2004-01-31Terminated(stopped due to 1. enrollment slower than anticipated; 2. FDA approval of droxidopa so no longer need to treat patients on research basis; 3. personnel who were primarily responsible for the study are no longer at Vanderbilt.)
A Double-blind, Randomized and Placebo-controlled Study to Evaluate the Efficacy and Safety of L-threo-3,4-dihydroxyphenylserine (Droxidopa) on Orthostatic Hypotension Treatment in Hemodialysis Patients [NCT01612078]Phase 325 participants (Actual)Interventional2012-06-30Terminated
A Two-Period Trial (Open-Label and Randomized Placebo-Controlled Substitution) of Droxidopa Treatment in Adults With ADHD With Co-administration of Carbidopa [NCT00983814]Phase 220 participants (Actual)Interventional2009-10-31Completed
Study of Droxidopa in Patients With Neurologic Hypotension [NCT00004478]0 participants Interventional1999-03-31Completed
A Double-Blinded, Placebo-Controlled Study To Assess Hemodynamic Changes, Orthostatic Tolerance, Out-Patient Fatigue And Quality Of Life In Neuropathic And Non-Neuropathic POTS Patients In Response To Adrenoreceptor Agonist And Antagonist [NCT03070730]Phase 1/Phase 28 participants (Actual)Interventional2011-08-15Terminated(stopped due to Recruitment was slow and subjects declined participation after signing the ICF.)
Treatment Trial of Droxidopa and Pyridostigmine to Improve Orthostatic Hypotension Without Aggravating Supine Hypertension [NCT01370512]Phase 230 participants (Anticipated)Interventional2011-11-30Suspended(stopped due to Plan to increase enrollment due to preliminary data having lower statistical power than anticipated.)
Evaluation of Brain Perfusion and Oxygenation in PD Patients With Neurogenic Orthostatic Hypotension: 4 Week Comparison of Droxidopa Versus Placebo [NCT03229174]Phase 417 participants (Actual)Interventional2018-08-23Completed
A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy [NCT01927055]Phase 361 participants (Actual)Interventional2013-11-30Terminated(stopped due to Due to potential competition with a post-marketing study requested by FDA)
Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism [NCT03446807]Phase 20 participants (Actual)Interventional2021-12-31Withdrawn(stopped due to Sponsor Decision to terminate)
The Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Aim 2 of RDCRN (Rare Diseases Clinical Research Network) Project 2 [NCT02897063]Phase 134 participants (Anticipated)Interventional2016-09-30Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00547911 (7) [back to overview]Diastolic Blood Pressures After 400 mg of Droxidopa + 200 mg of Either Placebo, Carbidopa, or Entacapone
NCT00547911 (7) [back to overview]Heart Rate After 400 mg of Droxidopa + 200 mg of Either Placebo, Carbidopa, or Entacapone
NCT00547911 (7) [back to overview]Plasma DHMA Concentrations After 400 mg of Droxidopa + 200 mg of Either Placebo, Carbidopa, or Entacapone
NCT00547911 (7) [back to overview]Plasma DHPG Concentrations After 400 mg of Droxidopa + 200 mg of Either Placebo, Carbidopa, or Entacapone
NCT00547911 (7) [back to overview]Plasma LDOPS Concentrations After 400 mg of Droxidopa + 200 mg of Either Placebo, Carbidopa, or Entacapone
NCT00547911 (7) [back to overview]Plasma Norepinephrine Concentrations After 400 mg of Droxidopa + 200 mg of Either Placebo, Carbidopa, or Entacapone
NCT00547911 (7) [back to overview]Systolic Blood Pressures After 400 mg of Droxidopa + 200 mg of Either Placebo, Carbidopa, or Entacapone
NCT00581477 (5) [back to overview]Change in Systolic Blood Pressure With Standing
NCT00581477 (5) [back to overview]Change in Systolic Blood Pressure With Standing
NCT00581477 (5) [back to overview]Change in Systolic Blood Pressure With Standing
NCT00581477 (5) [back to overview]Change in Systolic Blood Pressure With Standing
NCT00581477 (5) [back to overview]Change in Systolic Blood Pressure With Standing
NCT00633880 (11) [back to overview]Change in Concentration (OHSA Item 5)
NCT00633880 (11) [back to overview]Change in Vision (OHSA Item 2)
NCT00633880 (11) [back to overview]Change in Weakness (OHSA Item 3)
NCT00633880 (11) [back to overview]Change in Ability to Conduct Activities of Daily Living Score (OHDAS Composite Score)
NCT00633880 (11) [back to overview]Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1)
NCT00633880 (11) [back to overview]Change in Fatigue (OHSA Item 4)
NCT00633880 (11) [back to overview]Change in Head/Neck Discomfort (OHSA Item 6)
NCT00633880 (11) [back to overview]Change in Orthostatic Hypotension Questionnaire Score (OHQ)
NCT00633880 (11) [back to overview]Change in Orthostatic Hypotension Symptom Assessment Score (OHSA Composite)
NCT00633880 (11) [back to overview]Change in Orthostatic Hypotension Symptom Scores Excluding Dizziness (OHSA Composite Items 2-6)
NCT00633880 (11) [back to overview]Change in Systolic Blood Pressure (SBP) Measurements 3 Minutes Post Standing;
NCT00657046 (9) [back to overview]Number Patients With Hypotension Induced Early Termination of Dialysis Procedure
NCT00657046 (9) [back to overview]Systolic Blood Pressure Difference Between Pre-Hemodialysis and Nadir
NCT00657046 (9) [back to overview]Change in Average Mean Arterial Blood Pressure During Hemodialysis
NCT00657046 (9) [back to overview]Change in Average Mean Nadir Systolic Blood Pressures During Hemodialysis;
NCT00657046 (9) [back to overview]Change in Systolic Blood Pressure From Pre-dialysis to Post-dialysis
NCT00657046 (9) [back to overview]Change in the Hypotension-induced Symptom Severity Score
NCT00657046 (9) [back to overview]Change in the Multidimensional Fatigue Inventory (MFI-20)
NCT00657046 (9) [back to overview]Change in the Number of Hypotension-induced Interventions During Hemodialysis (HD) Sessions;
NCT00657046 (9) [back to overview]Daily Symptoms Associated With Hemodialysis
NCT00738062 (9) [back to overview]Change in Orthostatic Hypotension Symptom Assessment (OHSA) Composite Score
NCT00738062 (9) [back to overview]Patient Reported Clinical Global Impression - Severity
NCT00738062 (9) [back to overview]Patient Reported Clinical Global Impression - Improvement
NCT00738062 (9) [back to overview]Clinician Recorded Clinical Global Impression - Severity
NCT00738062 (9) [back to overview]Clinician Rated Clinical Global Impressions - Improvement
NCT00738062 (9) [back to overview]Change in Systolic Blood Pressure (SBP) Measurements 3 Minutes Post Standing
NCT00738062 (9) [back to overview]Change in Orthostatic Hypotension Questionnaire Composite Score (OHQ)
NCT00738062 (9) [back to overview]Change in Orthostatic Hypotension Daily Activities (OHDAS) Score
NCT00738062 (9) [back to overview]Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1)
NCT00782340 (9) [back to overview]Clinician-Reported Clinical Global Improvement - Severity Scores
NCT00782340 (9) [back to overview]Patient-Reported Clinical Global Improvement - Severity Scores
NCT00782340 (9) [back to overview]Change in Orthostatic Hypotension Symptom Assessment (OHSA Composite) Score
NCT00782340 (9) [back to overview]Change in Ability to Conduct Activities of Daily Living Score (OHDAS Composite Score)
NCT00782340 (9) [back to overview]Change in Activities Involving Standing a Short Time (OHDAS Item 1)
NCT00782340 (9) [back to overview]Change in Activities Involving Walking a Short Time (OHDAS Item 3)
NCT00782340 (9) [back to overview]Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1)
NCT00782340 (9) [back to overview]Change in Orthostatic Hypotension Questionnaire Score (OHQ)
NCT00782340 (9) [back to overview]Change in Systolic Blood Pressure (SBP) Measurements 3 Minutes Post Standing
NCT00977171 (1) [back to overview]Patient Global Impression of Improvement
NCT01132326 (1) [back to overview]Patients With Treatment-emergent Adverse Events
NCT01176240 (10) [back to overview]306B Efficacy: Change in OHSA Item 1 From Baseline to Week 2 (Visit 5)
NCT01176240 (10) [back to overview]Study 306A: Change in Dizziness/Lightheadedness/Feeling Faint/Feeling Like You Might Black Out (OHSA Item 1) From Baseline to Week 1
NCT01176240 (10) [back to overview]306A Efficacy: Change in Orthostatic Hypotension Questionnaire Score (OHQ)
NCT01176240 (10) [back to overview]306B Efficacy: Rate of Patient Reported Falls
NCT01176240 (10) [back to overview]306B Efficacy: Change in Systolic Blood Pressure (SBP) Measurements Post Standing From Baseline to Week 1
NCT01176240 (10) [back to overview]306B Efficacy: Change in Orthostatic Hypotension Questionnaire Score (OHQ)
NCT01176240 (10) [back to overview]306B Efficacy: Change in OHSA Item 1 From Baseline to Week 8 (Visit 7)
NCT01176240 (10) [back to overview]306B Efficacy: Change in OHSA Item 1 From Baseline to Week 4 (Visit 6)
NCT01176240 (10) [back to overview]306A Efficacy: Patient Reported Falls
NCT01176240 (10) [back to overview]306B Efficacy: Change in Dizziness/Lightheadedness/Feeling Faint/Feeling Like You Might Black Out (OHSA Item 1)
NCT01927055 (1) [back to overview]Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1)
NCT02586623 (7) [back to overview]Change From Randomization To All Post-randomization Visits in Orthostatic Hypotension Symptom Assessment (OHSA) Item #1 Score
NCT02586623 (7) [back to overview]Clinician-rated Clinical Global Impressions - Severity (CGI-S)
NCT02586623 (7) [back to overview]Participant-rated CGI-S
NCT02586623 (7) [back to overview]Time To All-cause Discontinuation
NCT02586623 (7) [back to overview]Time To Intervention
NCT02586623 (7) [back to overview]Number of Participants Who Needed Intervention During the 12-week Double-Blind Treatment Period
NCT02586623 (7) [back to overview]Change From Randomization To All Post-randomization Visits in Orthostatic Hypotension Questionnaire (OHQ) Composite Score
NCT03070730 (42) [back to overview]Change in Physical Functioning-OI From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-SF-36 Q From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-SF-36 Q From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-SF-36 Q From Baseline
NCT03070730 (42) [back to overview]Change in Vascular Resistance From Baseline
NCT03070730 (42) [back to overview]Change in Vascular Resistance From Baseline
NCT03070730 (42) [back to overview]Change in Vascular Resistance From Baseline
NCT03070730 (42) [back to overview]Change Maximal Postural Tachycardia During Tilt
NCT03070730 (42) [back to overview]Change Maximal Postural Tachycardia During Tilt
NCT03070730 (42) [back to overview]Change in Physical Functioning-FSS From Baseline
NCT03070730 (42) [back to overview]Change in Blood Pressure From Baseline
NCT03070730 (42) [back to overview]Change in Blood Pressure From Baseline
NCT03070730 (42) [back to overview]Change in Blood Pressure From Baseline
NCT03070730 (42) [back to overview]Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline
NCT03070730 (42) [back to overview]Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline
NCT03070730 (42) [back to overview]Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline
NCT03070730 (42) [back to overview]Change in Heart Rate From Baseline
NCT03070730 (42) [back to overview]Change in Heart Rate From Baseline
NCT03070730 (42) [back to overview]Change in Heart Rate From Baseline
NCT03070730 (42) [back to overview]Change in Maximal Postural Tachycardia During Tilt
NCT03070730 (42) [back to overview]Change in Muscle Sympathetic Nerve Activity From Baseline
NCT03070730 (42) [back to overview]Change in Muscle Sympathetic Nerve Activity From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning- HADS From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning- HADS From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning- HADS From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-CIS From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-CIS From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-CIS From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-EuroQOL From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-EuroQOL From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-EuroQOL From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-FSS From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-FSS From Baseline
NCT03070730 (42) [back to overview]Change in Muscle Sympathetic Nerve Activity From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-MFI From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-MFI From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-MFI From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-OI From Baseline
NCT03070730 (42) [back to overview]Change in Physical Functioning-OI From Baseline
NCT03115827 (4) [back to overview]Change in Stop-Signal Reaction Time From Baseline to Week 7
NCT03115827 (4) [back to overview]Maximum Tolerated Dose
NCT03115827 (4) [back to overview]Number of Subjects Who Develop an Adverse Event During the 7-week Treatment Period That is Determined to be Likely Related to the Study Medications.
NCT03115827 (4) [back to overview]Percent Compliance
NCT04510922 (7) [back to overview]Gait Analysis - Gait Velocity
NCT04510922 (7) [back to overview]Gait Analysis - Single Leg Stance Time
NCT04510922 (7) [back to overview]Gait Analysis - Stride Length
NCT04510922 (7) [back to overview]PDQ-39 Score
NCT04510922 (7) [back to overview]Postural Analysis - Postural Sway
NCT04510922 (7) [back to overview]Orthostatic Hypotension Questionnaire (OHQ) Score
NCT04510922 (7) [back to overview]Tinetti Score

Diastolic Blood Pressures After 400 mg of Droxidopa + 200 mg of Either Placebo, Carbidopa, or Entacapone

Diastolic blood pressure was assessed at baseline and after drug administration at 1 hour, 2 hours, 3 hours, 6 hours, and 24 hours. (NCT00547911)
Timeframe: Up to 24 hours after receiving drug(s)

,,
InterventionmmHg (Mean)
Baseline1 Hour2 Hour3 Hour6 Hour24 Hour
LDOPS + CAR818081848281
LDOPS + ENT788591918981
LDOPS + Placebo808586888984

[back to top]

Heart Rate After 400 mg of Droxidopa + 200 mg of Either Placebo, Carbidopa, or Entacapone

Heart rate was assessed at baseline and after drug administration at 1 hour, 2 hours, 3 hours, 6 hours, and 24 hours. (NCT00547911)
Timeframe: Up to 24 hours after receiving drug(s)

,,
InterventionBPM (Mean)
Baseline1 Hour2 Hour3 Hour6 Hour24 Hour
LDOPS + CAR666865646266
LDOPS + ENT676565646768
LDOPS + Placebo676566686766

[back to top]

Plasma DHMA Concentrations After 400 mg of Droxidopa + 200 mg of Either Placebo, Carbidopa, or Entacapone

Blood samples were obtained at baseline and after drug administration at 1 hour, 2 hours, 3 hours, 6 hours, 24 hours, and 48 hours to assess plasma droxymandelic acid (DHMA) concentrations. (NCT00547911)
Timeframe: Up to 48 hours after receiving drug(s)

,,
Interventionnmol/L (Mean)
Baseline1 Hour2 Hour3 Hour6 Hour24 Hour48 Hour
LDOPS + CAR1.662.541.521.701.743.243.00
LDOPS + ENT0.974.5815.0419.9133.032.210.90
LDOPS + Placebo0.14.010.111.015.71.40.9

[back to top]

Plasma DHPG Concentrations After 400 mg of Droxidopa + 200 mg of Either Placebo, Carbidopa, or Entacapone

Blood samples were obtained at baseline and after drug administration at 1 hour, 2 hours, 3 hours, 6 hours, 24 hours, and 48 hours to assess plasma dihydroxyphenylglycol (DHPG) concentrations. (NCT00547911)
Timeframe: Up to 48 hours after receiving drug(s)

,,
Interventionnmol/L (Mean)
Baseline1 Hour2 Hour3 Hour6 Hour24 Hour48 Hour
LDOPS + CAR3.43.53.33.63.53.83.7
LDOPS + ENT3.58.016.619.310.74.13.8
LDOPS + Placebo3.44.15.46.15.73.43.4

[back to top]

Plasma LDOPS Concentrations After 400 mg of Droxidopa + 200 mg of Either Placebo, Carbidopa, or Entacapone

Blood samples were obtained at baseline and after drug administration at 1 hour, 2 hours, 3 hours, 6 hours, 24 hours, and 48 hours to assess plasma droxidopa (LDOPS) concentrations. (NCT00547911)
Timeframe: Up to 48 hours after receiving drug(s)

,,
Interventionnmol/L (Mean)
Baseline1 Hour2 Hour3 Hour6 Hour24 Hour48 Hour
LDOPS + CAR0.00317317077905972421887
LDOPS + ENT0.897206891141200871723316
LDOPS + Placebo022467067869568432118

[back to top]

Plasma Norepinephrine Concentrations After 400 mg of Droxidopa + 200 mg of Either Placebo, Carbidopa, or Entacapone

Blood samples were obtained at baseline and after drug administration at 1 hour, 2 hours, 3 hours, 6 hours, 24 hours, and 48 hours to assess plasma norepinephrine concentrations. (NCT00547911)
Timeframe: Up to 48 hours after receiving drug(s)

,,
Interventionnmol/L (Mean)
Baseline1 Hour2 Hour3 Hour6 Hour24 Hour48 Hour
LDOPS + CAR0.850.870.981.120.980.890.85
LDOPS + ENT1.081.061.491.691.621.090.84
LDOPS + Placebo0.870.891.171.271.260.850.70

[back to top]

Systolic Blood Pressures After 400 mg of Droxidopa + 200 mg of Either Placebo, Carbidopa, or Entacapone

Systolic blood pressure was assessed at baseline and after drug administration at 1 hour, 2 hours, 3 hours, 6 hours, and 24 hours. (NCT00547911)
Timeframe: Up to 24 hours after receiving drug(s)

,,
InterventionmmHg (Mean)
Baseline1 Hour2 Hour3 Hour6 Hour24 Hour
LDOPS + CAR143144144148146143
LDOPS + ENT139149158161159144
LDOPS + Placebo140148163165161149

[back to top]

Change in Systolic Blood Pressure With Standing

The difference between upright and supine systolic blood pressures (dSBP; upright - supine) was calculated for each patient at 60-240 minutes after each dose of droxidopa. For each post-dose timepoint and study day, the average of up to three blood pressure readings per droxidopa dose was calculated. Dosing is individualized for each patient based upon how well the drug is tolerated and the degree of improvement in orthostatic vital signs and symptoms following drug administration. The dosages administered, as well as the number of timepoints and days, therefore, varied between patients. (NCT00581477)
Timeframe: Up to 240 minutes post dose on Study Days 1, 2, 3 and 4.

Interventionmillimeters of mercury (Median)
120 minutes post-dose (Day 1) dSBP60 minutes post-dose (Day 3) dSBP120 minutes post-dose (Day 3) dSBP120 minutes post-dose (Day 4) dSBP
Droxidopa 200 mg-31-51-36.5-19

[back to top]

Change in Systolic Blood Pressure With Standing

The difference between upright and supine systolic blood pressures (dSBP; upright - supine) was calculated for each patient at 60-240 minutes after each dose of droxidopa. For each post-dose timepoint and study day, the average of up to three blood pressure readings per droxidopa dose was calculated. Dosing is individualized for each patient based upon how well the drug is tolerated and the degree of improvement in orthostatic vital signs and symptoms following drug administration. The dosages administered, as well as the number of timepoints and days, therefore, varied between patients. (NCT00581477)
Timeframe: Up to 240 minutes post dose on Study Days 1, 2, 3 and 4.

Interventionmillimeters of mercury (Median)
60 minutes post-dose (Day 1) dSBP60 minutes post-dose (Day 2) dSBP120 minutes post-dose (Day 2) dSBP120 minutes post-dose (Day 3) dSBP60 minutes post-dose (Day 4) dSBP
Droxidopa 300 mg-21-30-13-23-21

[back to top]

Change in Systolic Blood Pressure With Standing

The difference between upright and supine systolic blood pressures (dSBP; upright - supine) was calculated for each patient at 60-240 minutes after each dose of droxidopa. For each post-dose timepoint and study day, the average of up to three blood pressure readings per droxidopa dose was calculated. Dosing is individualized for each patient based upon how well the drug is tolerated and the degree of improvement in orthostatic vital signs and symptoms following drug administration. The dosages administered, as well as the number of timepoints and days, therefore, varied between patients. (NCT00581477)
Timeframe: Up to 240 minutes post dose on Study Days 1, 2, 3 and 4.

Interventionmillimeters of mercury (Median)
60 minutes post-dose (Day 4) dSBP120 minutes post-dose (Day 4) dSBP
Droxidopa 250 mg-32.5-47

[back to top]

Change in Systolic Blood Pressure With Standing

The difference between upright and supine systolic blood pressures (dSBP; upright - supine) was calculated for each patient at 60-240 minutes after each dose of droxidopa. For each post-dose timepoint and study day, the average of up to three blood pressure readings per droxidopa dose was calculated. Dosing is individualized for each patient based upon how well the drug is tolerated and the degree of improvement in orthostatic vital signs and symptoms following drug administration. The dosages administered, as well as the number of timepoints and days, therefore, varied between patients. (NCT00581477)
Timeframe: Up to 240 minutes post dose on Study Days 1, 2, 3 and 4.

Interventionmillimeters of mercury (Median)
120 minutes post-dose (Day 1) dSBP60 minutes post-dose (Day 2) dSBP120 minutes post-dose (Day 2) dSBP
Droxidopa 100 mg-24-48-43.5

[back to top]

Change in Systolic Blood Pressure With Standing

The difference between upright and supine systolic blood pressures (dSBP; upright - supine) was calculated for each patient at 60-240 minutes after each dose of droxidopa. For each post-dose timepoint and study day, the average of up to three blood pressure readings per droxidopa dose was calculated. Dosing is individualized for each patient based upon how well the drug is tolerated and the degree of improvement in orthostatic vital signs and symptoms following drug administration. The dosages administered, as well as the number of timepoints and days, therefore, varied between patients. (NCT00581477)
Timeframe: Up to 240 minutes post dose on Study Days 1, 2, 3 and 4.

,
Interventionmillimeters of mercury (Median)
60 minutes post-dose (Day 1) dSBP120 minutes post-dose (Day 1) dSBP180 minutes post-dose (Day 1) dSBP240 minutes post-dose (Day 1) dSBP
Droxidopa 25 mg-47-39.5-38-47
Droxidopa 50 mg-39-35.5-4-7

[back to top]

Change in Concentration (OHSA Item 5)

OHSA item 5 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) . (NCT00633880)
Timeframe: 14 days

Interventionunits on a scale (Mean)
Droxidopa0.1
Placebo0.9

[back to top]

Change in Vision (OHSA Item 2)

OHSA item 2 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) . (NCT00633880)
Timeframe: 14 days

Interventionunits on a scale (Mean)
Droxidopa1.1
Placebo0.8

[back to top]

Change in Weakness (OHSA Item 3)

OHSA item 3 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) . (NCT00633880)
Timeframe: 14 days

Interventionunits on a scale (Mean)
Droxidopa0.3
Placebo1.2

[back to top]

Change in Ability to Conduct Activities of Daily Living Score (OHDAS Composite Score)

The OHDAS scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each asks the patient to rate their disease impact over the past week. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) . (NCT00633880)
Timeframe: 14 days

Interventionunits on a scale (Mean)
Droxidopa-0.24
Placebo0.91

[back to top]

Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1)

OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) . (NCT00633880)
Timeframe: 14 days

Interventionunits on a scale (Mean)
Droxidopa1.3
Placebo1.9

[back to top]

Change in Fatigue (OHSA Item 4)

OHSA item 4 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) . (NCT00633880)
Timeframe: 14 days

Interventionunits on a scale (Mean)
Droxidopa0.7
Placebo1.5

[back to top]

Change in Head/Neck Discomfort (OHSA Item 6)

OHSA item 6 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) . (NCT00633880)
Timeframe: 14 days

Interventionunits on a scale (Mean)
Droxidopa-0.1
Placebo1.2

[back to top]

Change in Orthostatic Hypotension Questionnaire Score (OHQ)

"The OHQ is the average of two sub-scales, the Orthostatic Hypotension Symptom Assessment Scale (OHSA) and the Orthostatic Hypotension Daily Activities Scale (OHDAS). Each asks the patient to rate their symptoms or disease impact over the past week. The OHSA sub-scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. The OHDAS sub-scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe.~In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) ." (NCT00633880)
Timeframe: 14 days

Interventionunits on a scale (Mean)
Droxidopa0.11
Placebo1.22

[back to top]

Change in Orthostatic Hypotension Symptom Assessment Score (OHSA Composite)

The OHSA scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. Each asks the patient to rate their symptoms over the past week. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) . (NCT00633880)
Timeframe: 14 days

Interventionunits on a scale (Mean)
Droxidopa0.6
Placebo1.35

[back to top]

Change in Orthostatic Hypotension Symptom Scores Excluding Dizziness (OHSA Composite Items 2-6)

OHSA composite scale (items 2-6) is the average of five OHSA items: 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. Each asks the patient to rate their symptoms over the past week. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) . (NCT00633880)
Timeframe: 14 days

Interventionunits on a scale (Mean)
Droxidopa0.44
Placebo1.07

[back to top]

Change in Systolic Blood Pressure (SBP) Measurements 3 Minutes Post Standing;

Change: standing systolic blood pressure at end of study minus standing systolic blood pressure at randomization. In this withdrawal design, a negative score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) . (NCT00633880)
Timeframe: 14 days

InterventionmmHg (Mean)
Droxidopa-7.6
Placebo-5.2

[back to top]

Number Patients With Hypotension Induced Early Termination of Dialysis Procedure

(NCT00657046)
Timeframe: 6 weeks

Interventionparticipants (Number)
Droxidopa 400mg3
Droxidopa 600mg1
Placebo7

[back to top]

Systolic Blood Pressure Difference Between Pre-Hemodialysis and Nadir

Change from baseline to end of study (HD visits 14-19) in systolic blood pressure difference between pre-hemodialysis and nadir. (NCT00657046)
Timeframe: 6 weeks

InterventionmmHg (Mean)
Droxidopa 400mg-5.88
Droxidopa 600mg-3.33
Placebo4.92

[back to top]

Change in Average Mean Arterial Blood Pressure During Hemodialysis

"Change between average baseline (visits 2-7) mean arterial blood pressure during hemodialysis and average treatment (visits 14-19) mean arterial blood pressure during hemodialysis.~The calculation of MAP was based on the systolic (SBP) and diastolic (DBP) blood pressure measurements taken during each valid HD session, using the traditional formula:~MAP = (SBP+2*DBP)/3 for each time-point. The mean of the intradialytic measurements was calculated for each valid HD session, and these daily mean values were averaged across the visits within each period." (NCT00657046)
Timeframe: 6 weeks

InterventionmmHg (Mean)
Droxidopa 400mg-0.12
Droxidopa 600mg1.95
Placebo1.60

[back to top]

Change in Average Mean Nadir Systolic Blood Pressures During Hemodialysis;

Change between baseline (visits 2-7) and treatment (visits 14-19) in average mean nadir systolic blood pressures during hemodialysis. The baseline value will be the arithmetic average of the values collected at each of the six baseline visits (visits 2-7). The on treatment value will be defined as the average of the values collected at each of the last six treatment visits (visits 14-19). (NCT00657046)
Timeframe: 6 weeks

InterventionmmHg (Mean)
Droxidopa 400mg3.09
Droxidopa 600mg2.60
Placebo-0.35

[back to top]

Change in Systolic Blood Pressure From Pre-dialysis to Post-dialysis

"Change from baseline (visits 2-7) to end of study (HD visits 14-19) in the drop in systolic blood pressure from pre-hemodialysis to 5 minutes post-hemodialysis.~The baseline value was the arithmetic average of the values collected at each of the six baseline visits (visits 2-7). The on treatment value was defined as the average of the values collected at each of the last six treatment visits (visits 14-19)." (NCT00657046)
Timeframe: 6 weeks

InterventionmmHg (Mean)
Droxidopa 400mg3.41
Droxidopa 600mg4.77
Placebo-4.39

[back to top]

Change in the Hypotension-induced Symptom Severity Score

"The hypotension-induced symptom severity score is the sum of a 6 question scale (each rated 0 [asymptomatic] to 4 [severe]). The questions look at cramps, dizziness, headache, nausea, itchiness, and restless legs syndrome experienced during dialysis.~The outcome looks at the difference between the average baseline score (visits 2-7) and the average on-treatment scores (visits 14-19). The baseline value will be the arithmetic average of the values collected at each of the six baseline visits (visits 2-7). The on treatment value will be defined as the average of the values collected at each of the last six treatment visits (visits 14-19)." (NCT00657046)
Timeframe: 6 weeks

Interventionunits on a scale (Mean)
Droxidopa 400mg-0.9
Droxidopa 600mg-1.2
Placebo-1.2

[back to top]

Change in the Multidimensional Fatigue Inventory (MFI-20)

"Fatigue will be measured by the general fatigue domain (items 1, 5, 12 and 16) of MFI-20 and will be summarized by treatment group and treatment period. The scores per item run from 1 to 5. A higher score indicates more fatigue. Therefore, the items indicative for fatigue need to be recoded (1=5, 2=4, 3=3, 4=2, 5=1). This concerns item: 5 and 16. A total score is calculated by summation of the scores of the individual items. Scores can range from the minimum of 4 to the maximum of 20.~The value at baseline (visit 7) will be subtracted from the value on treatment (visit 19 or visit 13 if visit 19 is not available)." (NCT00657046)
Timeframe: 6 weeks

Interventionunits on a scale (Mean)
Droxidopa 400mg-0.1
Droxidopa 600mg-0.3
Placebo0.6

[back to top]

Change in the Number of Hypotension-induced Interventions During Hemodialysis (HD) Sessions;

Evaluate the efficacy of droxidopa as measured by change in the number of hypotension-induced interventions during hemodialysis (HD) sessions between baseline (visits 2-7) and treatment (visits 14-19). The baseline value will be the arithmetic average of the values collected at each of the six baseline visits (visits 2-7). The on treatment value will be defined as the average of the values collected at each of the last six treatment visits (visits 14-19). (NCT00657046)
Timeframe: 6 weeks

Interventionaverage interventions per session (Mean)
Droxidopa 400mg-0.2
Droxidopa 600mg-0.2
Placebo-0.1

[back to top]

Daily Symptoms Associated With Hemodialysis

"The Daily symptoms associated with hemodialysis score is the sum of an 8 question scale (each rated 0 [asymptomatic] to 4 [severe]). The questions look at fatigability, malaise/weakness, physical disturbance on standing, coldness of limbs, dizziness/lightheadedness, dizziness on standing, general bad feeling, and sleep disorders and asks how each of these items affected the patients daily activities on that day.~The outcome looks at the difference between the average baseline score (visits 2-7) and the average on-treatment scores (visits 14-19). The baseline value will be the arithmetic average of the values collected at each of the six baseline visits (visits 2-7). The on treatment value will be defined as the average of the values collected at each of the last six treatment visits (visits 14-19)." (NCT00657046)
Timeframe: 6 weeks

Interventionunits on a scale (Mean)
Droxidopa 400mg-0.13
Droxidopa 600mg-1.33
Placebo-1.34

[back to top]

Change in Orthostatic Hypotension Symptom Assessment (OHSA) Composite Score

"The OHSA scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. Each asks the patient to rate their symptoms over the past week. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe.~Change: score at end of randomization minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug)." (NCT00738062)
Timeframe: 14 days

Interventionunits on a scale (Mean)
Droxidopa0.59
Placebo1.10

[back to top]

Patient Reported Clinical Global Impression - Severity

"The CGI-S is a 7 point scale ranging from a score of 1 (no symptoms) to 7 (severe symptoms). Patients were grouped according to OH severity at the end of the randomization period as follows;~Normal-Borderline OH (CGI-S 1-2),~Mild-Moderate OH (CGI-S 3-4),~Marked OH-Most Ill with OH (CGI-S 5-7). ." (NCT00738062)
Timeframe: 14 days

,
Interventionparticipants (Number)
Normal-Borderline OHMild-Moderate OHMarked OH-Most ill with OH
Droxidopa13169
Placebo121312

[back to top]

Patient Reported Clinical Global Impression - Improvement

"The CGI-I is a 7 point scale ranging from a score of 1 (very much improved) to 7 (very much worse), with no change in the middle, and assesses the improvement in relation to the baseline evaluation.~Patients will be grouped according change in disease as follows;~Very Much Improved to Slightly Improved (CGI-I 1-3),~No Change (CGI-I 4),~Slightly Worse to Very Much Worse (CGI-I 5-7)." (NCT00738062)
Timeframe: 14 days

,
Interventionparticipants (Number)
Very much - Slightly ImprovedNo ChangeSlightly - Very much Worse
Droxidopa2576
Placebo20512

[back to top]

Clinician Recorded Clinical Global Impression - Severity

"The CGI-S is a 7 point scale ranging from a score of 1 (no symptoms) to 7 (severe symptoms). Patients were grouped according to OH severity at the end of the randomization period as follows;~Normal-Borderline OH (CGI-S 1-2),~Mild-Moderate OH (CGI-S 3-4),~Marked OH-Most Ill with OH (CGI-S 5-7)." (NCT00738062)
Timeframe: 14 days

,
Interventionparticipants (Number)
Normal-Borderline OHMild-Moderate OHMarked OH-Most ill with OH
Droxidopa91613
Placebo71515

[back to top]

Clinician Rated Clinical Global Impressions - Improvement

"The CGI-I is a 7 point scale ranging from a score of 1 (very much improved) to 7 (very much worse), with no change in the middle, and assesses the improvement in relation to the baseline evaluation.~Patients will be grouped according change in disease as follows;~Very Much Improved to Slightly Improved (CGI-I 1-3),~No Change (CGI-I 4),~Slightly Worse to Very Much Worse (CGI-I 5-7)." (NCT00738062)
Timeframe: 14 days

,
Interventionparticipants (Number)
Very much - Slightly ImprovedNo ChangeSlightly - Very much Worse
Droxidopa2648
Placebo2089

[back to top]

Change in Systolic Blood Pressure (SBP) Measurements 3 Minutes Post Standing

Change: standing systolic blood pressure at end of study minus standing systolic blood pressure at randomization. In this withdrawal design, a negative score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug). All patients are on open-label droxidopa for 3 months prior to randomization to either continued droxidopa or to placebo. (NCT00738062)
Timeframe: 14 days

InterventionmmHg (Mean)
Droxidopa-8.4
Placebo0.0

[back to top]

Change in Orthostatic Hypotension Questionnaire Composite Score (OHQ)

"The OHQ is the average of two sub-scales, the Orthostatic Hypotension Symptom Assessment Scale (OHSA) and the Orthostatic Hypotension Daily Activities Scale (OHDAS). Each asks the patient to rate their symptoms or disease impact over the past week. The OHSA sub-scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. The OHDAS sub-scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe.~In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug). All patients are on open-label droxidopa for 3 months prior to randomization." (NCT00738062)
Timeframe: 14 days

Interventionunits on a scale (Mean)
Droxidopa0.57
Placebo0.90

[back to top]

Change in Orthostatic Hypotension Daily Activities (OHDAS) Score

"The OHDAS scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each asks the patient to rate their disease impact over the past week. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe.~Change: score at end of randomization minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug)." (NCT00738062)
Timeframe: 14 days

Interventionunits on a scale (Mean)
Droxidopa0.53
Placebo0.71

[back to top]

Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1)

OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug). All patients were on open-label droxidopa for 3 months prior to randomization to either continued droxidopa or to placebo. (NCT00738062)
Timeframe: 14 days

Interventionunits on a scale (Mean)
Droxidopa0.9
Placebo1.3

[back to top]

Clinician-Reported Clinical Global Improvement - Severity Scores

"The CGI-S is a 7 point scale ranging from a score of 1 (no symptoms) to 7 (severe symptoms). Patients were grouped according to OH severity at the end of the randomization period as follows;~Normal-Borderline OH (CGI-S 1-2), Mild-Moderate OH (CGI-S 3-4), Marked OH-Most Ill with OH (CGI-S 5-7)." (NCT00782340)
Timeframe: 7 days

,
Interventionparticipants (Number)
Normal-Borderline OHMild-Moderate OHMarked OH-Most ill with OH
Droxidopa213922
Placebo154421

[back to top]

Patient-Reported Clinical Global Improvement - Severity Scores

"The CGI-S is a 7 point scale ranging from a score of 1 (no symptoms) to 7 (severe symptoms). Patients were grouped according to OH severity at the end of the randomization period as follows;~Normal-Borderline OH (CGI-S 1-2), Mild-Moderate OH (CGI-S 3-4), Marked OH-Most Ill with OH (CGI-S 5-7)." (NCT00782340)
Timeframe: 7 days

,
Interventionparticipants (Number)
Normal-Borderline OHMild-Moderate OHMarked OH-Most ill with OH
Droxidopa233920
Placebo164717

[back to top]

Change in Orthostatic Hypotension Symptom Assessment (OHSA Composite) Score

OHSA composite scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. A negative score indicates an improvement during the double-blind randomized phase relative to value at randomization. (NCT00782340)
Timeframe: 7 days

Interventionunits on a scale (Mean)
Droxidopa-1.68
Placebo-0.95

[back to top]

Change in Ability to Conduct Activities of Daily Living Score (OHDAS Composite Score)

OHDAS composite scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. A negative score indicates an improvement during the double-blind randomized phase relative to value at randomization. (NCT00782340)
Timeframe: 7 days

Interventionunits on a scale (Mean)
Droxidopa-1.98
Placebo-0.92

[back to top]

Change in Activities Involving Standing a Short Time (OHDAS Item 1)

OHDAS Item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. A negative score indicates an improvement during the double-blind randomized phase relative to value at randomization. (NCT00782340)
Timeframe: 7 days

Interventionunits on a scale (Mean)
Droxidopa-1.9
Placebo-0.8

[back to top]

Change in Activities Involving Walking a Short Time (OHDAS Item 3)

OHDAS Item 3 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. A negative score indicates an improvement during the double-blind randomized phase relative to value at randomization. (NCT00782340)
Timeframe: 7 days

Interventionunits on a scale (Mean)
Droxidopa-1.7
Placebo-0.6

[back to top]

Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1)

OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. A negative score indicates an improvement during the double-blind randomized phase relative to value at randomization. (NCT00782340)
Timeframe: 7 days

Interventionunits on a scale (Mean)
Droxidopa-2.4
Placebo-1.1

[back to top]

Change in Orthostatic Hypotension Questionnaire Score (OHQ)

"The OHQ is the average of two sub-scales, the Orthostatic Hypotension Symptom Assessment Scale (OHSA) and the Orthostatic Hypotension Daily Activities Scale (OHDAS). Each asks the patient to rate their symptoms or disease impact over the past week. The OHSA sub-scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. The OHDAS sub-scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe.~For the change from randomization, negative numbers represent improvement from randomization in OHQ score." (NCT00782340)
Timeframe: 7 days

Interventionunits on a scale (Mean)
Droxidopa-1.83
Placebo-0.93

[back to top]

Change in Systolic Blood Pressure (SBP) Measurements 3 Minutes Post Standing

Change: standing systolic blood pressure at end of study minus standing systolic blood pressure at randomization. A positive score indicates an improvement during the double-blind randomized phase relative to value at randomization. (NCT00782340)
Timeframe: 7 days

InterventionmmHg (Mean)
Droxidopa11.2
Placebo3.9

[back to top]

Patient Global Impression of Improvement

The CGI-I is a 7 point scale ranging from a score of 1 (very much improved) to 7 (very much worse), with no change in the middle, and assesses the improvement in relation to the baseline evaluation. (NCT00977171)
Timeframe: Baseline to end of 12 week treatment period

Interventionunits on a scale (Mean)
Droxidopa3

[back to top]

Patients With Treatment-emergent Adverse Events

Number of patients reporting any treatment emergent adverse events (SAE and or AEs) during the study (NCT01132326)
Timeframe: up to 2 years

Interventionparticipants (Number)
Droxidopa263

[back to top]

306B Efficacy: Change in OHSA Item 1 From Baseline to Week 2 (Visit 5)

OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 2 minus score at baseline. A negative score indicates an improvement in symptoms during the double-blind randomized phase relative to value at baseline. (NCT01176240)
Timeframe: Baseline, Week2

Interventionunits on a scale (Mean)
Droxidopa-1.9
Placebo-1.6

[back to top]

Study 306A: Change in Dizziness/Lightheadedness/Feeling Faint/Feeling Like You Might Black Out (OHSA Item 1) From Baseline to Week 1

OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 1 minus score at baseline. A negative score indicates improvement in symptoms during the double-blind randomized phase relative to value at baseline. (NCT01176240)
Timeframe: Baseline, Week 1

Interventionunits on a scale (Mean)
Droxidopa-3.1
Placebo-1.6

[back to top]

306A Efficacy: Change in Orthostatic Hypotension Questionnaire Score (OHQ)

"The primary efficacy endpoint for 306A is the relative mean change in Orthostatic Hypotension Questionnaire (OHQ) composite score from baseline to end of study. The OHQ is the average of two sub-scales, the Orthostatic Hypotension Symptom Assessment Scale (OHSA) and the Orthostatic Hypotension Daily Activities Scale (OHDAS). Each asks the patient to rate their symptoms or disease impact over the past week. The OHSA sub-scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. The OHDAS sub-scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe.~For the change from baseline, negative numbers represent improvement from baseline in OHQ score." (NCT01176240)
Timeframe: Baseline, Week 8

Interventionunits on a scale (Mean)
Droxidopa-2.2
Placebo-2.1

[back to top]

306B Efficacy: Rate of Patient Reported Falls

The average number of patient reported falls per week. (NCT01176240)
Timeframe: up to 10 weeks

Interventionfalls per week (Mean)
Droxidopa0.4
Placebo2.0

[back to top]

306B Efficacy: Change in Systolic Blood Pressure (SBP) Measurements Post Standing From Baseline to Week 1

Measure: Lowest standing systolic blood pressure reading of immediately post standing and 3 minutes post standing. Change: standing systolic blood pressure at Week 1 (Visit 4) minus standing systolic blood pressure at baseline. A positive score indicates an improvement in standing systolic blood pressure during the double-blind randomized phase relative to value at baseline. (NCT01176240)
Timeframe: Baseline, Week 1

InterventionmmHg (Mean)
Droxidopa6.4
Placebo0.7

[back to top]

306B Efficacy: Change in Orthostatic Hypotension Questionnaire Score (OHQ)

"The relative mean change in Orthostatic Hypotension Questionnaire (OHQ) composite score from baseline to end of study. The OHQ is the average of two sub-scales, the Orthostatic Hypotension Symptom Assessment Scale (OHSA) and the Orthostatic Hypotension Daily Activities Scale (OHDAS). Each asks the patient to rate their symptoms or disease impact over the past week. The OHSA sub-scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. The OHDAS sub-scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe.~For the change from baseline, negative numbers represent improvement from baseline in OHQ score." (NCT01176240)
Timeframe: Baseline, Week 8

Interventionunits on a scale (Mean)
Droxidopa-2.2
Placebo-2.0

[back to top]

306B Efficacy: Change in OHSA Item 1 From Baseline to Week 8 (Visit 7)

OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 8 minus score at baseline. A negative score indicates an improvement in symptoms during the double-blind randomized phase relative to value at baseline. (NCT01176240)
Timeframe: Baseline, Week 8

Interventionunits on a scale (Mean)
Droxidopa-2.1
Placebo-1.5

[back to top]

306B Efficacy: Change in OHSA Item 1 From Baseline to Week 4 (Visit 6)

OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 4 minus score at baseline. A negative score indicates an improvement in symptoms during the double-blind randomized phase relative to value at baseline. (NCT01176240)
Timeframe: Baseline, Week4

Interventionunits on a scale (Mean)
Droxidopa-2.0
Placebo-1.5

[back to top]

306A Efficacy: Patient Reported Falls

The total number of patient reported falls during the 8 week treatment period (NCT01176240)
Timeframe: Baseline, Week 8

Interventiontotal falls per group (Number)
Droxidopa79
Placebo192

[back to top]

306B Efficacy: Change in Dizziness/Lightheadedness/Feeling Faint/Feeling Like You Might Black Out (OHSA Item 1)

OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 1 minus score at baseline. A negative score indicates an improvement in symptoms during the double-blind randomized phase relative to value at baseline. (NCT01176240)
Timeframe: Baseline, Week1

Interventionunits on a scale (Mean)
Droxidopa-2.3
Placebo-1.3

[back to top]

Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1)

OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. A positive score indicates worsening during the double-blind randomized phase relative to value at randomization, while a negative score indicates an improvement in symptom severity. (NCT01927055)
Timeframe: Change from Randomization to Week 1

Interventionunits on a scale (Mean)
Droxidopa-1.1
Placebo-0.5

[back to top]

Change From Randomization To All Post-randomization Visits in Orthostatic Hypotension Symptom Assessment (OHSA) Item #1 Score

The OHSA scale was designed to rate symptoms occurring specifically as a result of low blood pressure (BP), on average, over the past week using an 11-point scale (0 to 10), with more severe symptoms scoring higher. A score of zero indicates that the symptom was not experienced, and 10 is the worst possible. The scale was used to assess six symptoms: 1) Dizziness, lightheadedness, feeling faint, or feeling like you might black out, 2) problems with vision, 3) weakness, 4) fatigue, 5) trouble concentrating, and 6) head/neck discomfort. Scores for each activity and a composite score for all six activities were tabulated. A mean negative change from baseline means that symptoms have improved. A mean positive change from baseline means that symptoms have gotten worse. (NCT02586623)
Timeframe: Randomization (Day 0); Weeks 2 to 12

,
InterventionScore on a scale (Mean)
Week 2Week 4Week 6Week 8Week 10Week 12
Double-Blind Droxidopa0.50.30.30.2-0.30.1
Double-Blind Placebo0.50.30.10.0-0.5-0.5

[back to top]

Clinician-rated Clinical Global Impressions - Severity (CGI-S)

The CGI-S was developed to provide global measures of the severity of a participant's clinical condition during clinical studies. The CGI-S was utilized by both the clinician and the participant to provide an impression of the participant's current state of OH. The severity of the participant's current illness was rated by the clinician on a 7-point scale ranging from 1 (normal, no OH) to 7 (among those patients most extremely ill with OH). (NCT02586623)
Timeframe: Weeks 2 to 12

,
InterventionScore on a scale (Mean)
Week 2Week 4Week 6Week 8Week 10Week 12
Double-Blind Droxidopa3.43.13.23.23.03.0
Double-Blind Placebo3.33.33.23.13.02.9

[back to top]

Participant-rated CGI-S

The CGI-S was developed to provide global measures of the severity of a participant's clinical condition during clinical studies. The CGI-S was utilized by both the clinician and the participant to provide an impression of the participant's current state of OH. The severity of the participant's current illness was rated by the participant on a 7-point scale ranging from 1 (normal, no OH) to 7 (most extremely ill with OH). (NCT02586623)
Timeframe: Weeks 2 to 12

,
InterventionScore on a scale (Mean)
Week 2Week 4Week 6Week 8Week 10Week 12
Double-Blind Droxidopa3.43.23.23.23.13.1
Double-Blind Placebo3.23.33.13.13.02.8

[back to top]

Time To All-cause Discontinuation

Kaplan-Meier estimates are presented for time to all-cause discontinuation. The estimates represent the quartiles of the survival time, where 50% corresponds to the median time to discontinuation. Time to all-cause discontinuation was defined as the time from randomization to withdrawal or last contact date. (NCT02586623)
Timeframe: Randomization (Day 0) up to Week 12

,
InterventionDays (Number)
25%50%75%
Double-Blind Droxidopa42.00NANA
Double-Blind Placebo51.00NANA

[back to top]

Time To Intervention

"Kaplan-Meier estimates are presented for time to treatment intervention. The estimates represent the quartiles of the survival time, where 50% corresponds to the median time to need for treatment intervention.~Need for intervention is defined as meeting ANY of the following criteria during the Double-Blind Treatment Period:~OHSA Item #1 ≥2 unit worsening from Randomization (Visit 6) AND lack of efficacy as judged by the investigator; OR~OHSA Item #1 ≥2 unit worsening from Randomization (Visit 6) at 2 consecutive visits; OR~OHSA Item #1 ≥2 unit worsening from Randomization (Visit 6) at the visit before early discontinuation; OR~participant stops IMP or withdraws from study for patient-reported lack of efficacy." (NCT02586623)
Timeframe: Randomization (Day 0) up to Week 12

,
InterventionDays (Number)
25%50%75%
Double-Blind Droxidopa52.00NANA
Double-Blind Placebo42.00NANA

[back to top]

Number of Participants Who Needed Intervention During the 12-week Double-Blind Treatment Period

"Need for intervention is defined as meeting ANY of the following criteria during the Double-Blind Treatment Period:~OHSA Item #1 ≥2 unit worsening from Randomization (Visit 6) AND lack of efficacy as judged by the investigator; OR~OHSA Item #1 ≥2 unit worsening from Randomization (Visit 6) at 2 consecutive visits; OR~OHSA Item #1 ≥2 unit worsening from Randomization (Visit 6) at the visit before early discontinuation; OR~participant stops IMP or withdraws from study for patient-reported lack of efficacy." (NCT02586623)
Timeframe: Randomization (Day 0) up to Week 12

InterventionParticipants (Count of Participants)
Double-Blind Droxidopa41
Double-Blind Placebo40

[back to top]

Change From Randomization To All Post-randomization Visits in Orthostatic Hypotension Questionnaire (OHQ) Composite Score

"The OHQ composite score was a mean of the OHSA composite and the Orthostatic Hypotension Daily Activity Scale (OHDAS) composite scores. The OHDAS was designed as a measure of quality of life. It uses an 11-point scale to assess whether orthostatic hypotension (OH) interfered with four types of activities: 1) standing for a short time, 2) standing for a long time, 3) walking for a short time, and 4) walking for a long time. A zero rating means that over the preceding week the activity was performed with no interference and a 10 rating means that orthostatic hypotension completely interfered with the activity. Scores for each activity and a composite score for all four activities were tabulated. A mean negative change from baseline means that symptoms have improved. A mean positive change from baseline means that symptoms have gotten worse." (NCT02586623)
Timeframe: Randomization (Day 0); Weeks 2 to 12

,
InterventionScore on a scale (Mean)
Week 2Week 4Week 6Week 8Week 10Week 12
Double-Blind Droxidopa0.410.210.120.10-0.19-0.08
Double-Blind Placebo0.400.10-0.05-0.25-0.56-0.57

[back to top]

Change in Physical Functioning-OI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-SF-36 Q From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-SF-36 Q From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-SF-36 Q From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Vascular Resistance From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Vascular Resistance From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Vascular Resistance From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change Maximal Postural Tachycardia During Tilt

Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: 2 weeks after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change Maximal Postural Tachycardia During Tilt

Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: 2 weeks after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-FSS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Blood Pressure From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Blood Pressure From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Blood Pressure From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline

A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: 2 weeks after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline

A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: 2 weeks after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline

A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: up to 3 days after randomization

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Heart Rate From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Heart Rate From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Heart Rate From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Maximal Postural Tachycardia During Tilt

Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: Up to 3 days after randomization

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Muscle Sympathetic Nerve Activity From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Muscle Sympathetic Nerve Activity From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline

"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline

"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline

"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning- HADS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning- HADS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning- HADS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-CIS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-CIS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-CIS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-EuroQOL From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-EuroQOL From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-EuroQOL From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-FSS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-FSS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Muscle Sympathetic Nerve Activity From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-MFI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-MFI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-MFI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-OI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Physical Functioning-OI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

[back to top]

Change in Stop-Signal Reaction Time From Baseline to Week 7

The Stop-Signal reaction time is a computerized test that assesses reaction time and response inhibition (NCT03115827)
Timeframe: baseline and week 7

Interventionchange in SSRT in seconds (Mean)
Arm 1-14.38

[back to top]

Maximum Tolerated Dose

The mean maximum tolerated dose of droxidopa reached by the study participants (NCT03115827)
Timeframe: Week 4 to Week 7

Interventionmg/day (Mean)
Arm 11053

[back to top] [back to top]

Percent Compliance

Percent compliance is defined as the percent of study participants who take greater than or equal to 70% of the assigned dosage (NCT03115827)
Timeframe: 7 weeks

InterventionParticipants (Count of Participants)
Arm 111

[back to top]

Gait Analysis - Gait Velocity

"Using a gait mat, participants were instructed to walk self-paced on the mat, turn around, and walk back. Their velocity was measured in cm/sec.~This output was compared pre- and post- 6 week dosing with study medication." (NCT04510922)
Timeframe: 6 weeks

Interventioncm/sec (Mean)
Droxidopa112.1

[back to top]

Gait Analysis - Single Leg Stance Time

Using a gait mat, participants were instructed to walk self-paced along the mat. The sensors in the mat automatically extracted the percentage of time a participant stood on a single leg. The output was compared pre- and post- 6 week dosing with study medication. (NCT04510922)
Timeframe: 6 weeks

Interventionpercentage of time (Mean)
Droxidopa34.6

[back to top]

Gait Analysis - Stride Length

Measured in cm (NCT04510922)
Timeframe: 1 month

Interventioncm (Mean)
Droxidopa60.3

[back to top]

PDQ-39 Score

"The Parkinson's Disease Questionnaire (PDQ-39) assesses how often people with Parkinson's experience difficulties across 8 dimensions of daily living including mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort.~The scale consists of 39 items ranked on a 5-point ordinal scale (Never=0, Occasionally=1, Sometimes=2, Often=3, Always=4).~Each dimension total score range from 0 (never have difficulty) to 100 (always have difficulty). Lower scores reflect better Quality of Life.~Dimension score = sum of scores of each item in the dimension divided by the maximum possible score of all the items in the dimension, multiplied by 100.~Overall score = sum of dimension total scores divided by 8.~Scores were compared pre- and post- 6 weeks dosing with medication." (NCT04510922)
Timeframe: 6 weeks

Interventionscore on a scale (Mean)
Droxidopa31

[back to top]

Postural Analysis - Postural Sway

Using a gait mat, postural sway was measured in cm on the X-axis while participants were asked to stand eyes open and eyes closed for 30 seconds. This output was compared pre- and post- 6 weeks dosing with study medication. (NCT04510922)
Timeframe: 6 weeks

Interventioncm (Mean)
Droxidopa35.8

[back to top]

Orthostatic Hypotension Questionnaire (OHQ) Score

Orthostatic Hypotension Symptom Assessment (OHSA; Range: 0-10) and Orthostatic Hypotension Daily Activities Scale (OHDAS; Range: 0-10) 10 items measured on a Likert-scale with 10 being the worst possible score. (NCT04510922)
Timeframe: 1 month

Interventionscore on a scale (Mean)
Droxidopa4.6

[back to top]

Tinetti Score

"he Tinetti assessment tool is an easily administered task-oriented test that measures an older adult's gait and balance abilities. Scoring: Items are scored either 0-1 or 0-2. 0 indicates the highest level of impairment, whereas a higher score (1 or 2) indicates the individuals independence.~There were 17 tasks (one task split into two sub-items and scored twice) that the scores were summed for a highest possible score of 28 (10 items scored on a 0-1 scale, and 8 items scored on a 0-2 scale).~The Tinetti assessment was compared pre- and post- 6 week medication dosing." (NCT04510922)
Timeframe: 6 weeks

Interventionscore on a scale (Mean)
Droxidopa13.4

[back to top]